---
title: "TLX: Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293260434.md"
description: "Q2 2026 revenue rose 21% YoY to US $247M, with Precision Medicine up 30% YoY. Strategic collaboration with Regeneron and expanded global operations support guidance for FY 2026 revenue and other income to exceed US $1riginal document: Telix Pharmaceuticals Limited [TLX] Earnings Release — Jul. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-20T22:41:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293260434.md)
  - [en](https://longbridge.com/en/news/293260434.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293260434.md)
---

# TLX: Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B

Q2 2026 revenue rose 21% YoY to US $247M, with Precision Medicine up 30% YoY. Strategic collaboration with Regeneron and expanded global operations support guidance for FY 2026 revenue and other income to exceed US $1B.

Original document: Telix Pharmaceuticals Limited \[TLX\] Earnings Release — Jul. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)

## Related News & Research

- [Regeneron publishes corporate presentation highlighting Q2 pipeline progress and product sales trends](https://longbridge.com/en/news/294365385.md)
- [Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS](https://longbridge.com/en/news/294080297.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [RACE: Q2 2026 revenues up 8.4% year-over-year, 2026 guidance raised on strong demand and mix](https://longbridge.com/en/news/294352191.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)